menu search

AQST / Aquestive Therapeutics: Waiting To Buy After FDA Goes Halfway With Libervant

Aquestive Therapeutics: Waiting To Buy After FDA Goes Halfway With Libervant
After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestive's Libervant. Unfortunately, the company cannot market the product. Aquestive Therapeutics recently reported their Q2 earnings, which revealed a beat on revenue with the EPS in-line with expectations. Aquestive has upped their full-year guidance for both revenue and EPS. Read More
Posted: Sep 2 2022, 13:38
Author Name: Seeking Alpha
Views: 111555

AQST News  

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

By Zacks Investment Research
November 1, 2023

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close. more_horizontal

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

By Zacks Investment Research
October 9, 2023

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day. more_horizontal

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

By Seeking Alpha
September 22, 2023

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture sign more_horizontal

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

By Zacks Investment Research
September 13, 2023

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day. more_horizontal

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

By Zacks Investment Research
September 12, 2023

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure more_horizontal

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 7, 2023

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares more_horizontal

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

By Zacks Investment Research
July 26, 2023

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues. more_horizontal

Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem

By Seeking Alpha
July 25, 2023

Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem

Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/ more_horizontal


Search within

Pages Search Results: